Page last updated: 2024-12-07

3-aminobenzeneboronic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID92269
CHEMBL ID20852
SCHEMBL ID22913
MeSH IDM0091852

Synonyms (65)

Synonym
einecs 266-376-5
3-aminophenylboric acid hemisulphate
nsc 87958
m-aminophenylboronic acid
DB01896
NCGC00092011-01
3-aminophenylboronic acid ,
30418-59-8
STK503698
(3-aminophenyl)boronic acid
A1281
3-aminophenyl boronic acid
CHEMBL20852 ,
3-aminobenzeneboronic acid
bdbm50067906
(3-aminophenyl)boronic acid, 1
NCGC00092011-02
m-aminophenyl boronic acid
3-amino phenylboronic acid
meta-aminophenylboronic acid
einecs 250-189-0
m-aminobenzeneboronic acid
44u8adr772 ,
unii-44u8adr772
(m-aminophenyl)metaboric acid
AKOS005171625
3-boronoaniline
FT-0615022
AS-2507
AB00895
SCHEMBL22913
3aminophenyl boronic acid
3-amino-phenylboronic acid
3-amino-benzeneboronic acid
3-(amino)-phenylboronic acid
JMZFEHDNIAQMNB-UHFFFAOYSA-N
(3-aminophenyl)-boronic acid
3-amino phenyl boronic acid
3-amino benzene boronic acid
(3-amino-phenyl)-boronic acid
3amino phenylboronic acid
3-amino-phenyl boronic acid
3-(amino)-phenyl boronic acid
3-aminobenzene boronic acid
boronic acid, (3-aminophenyl)-
mfcd00007755
J-511716
m-aminophenylboronic acid-agarose, aqueous suspension
m-aminophenylboronic acid-agarose, saline suspension
3-aminophenylboronic acid, aldrichcpr
J-017951
CS-W018320
BCP23044
SY003592
3-aminophenyl(dihydroxy)borane
Q27093011
DTXSID10867227
EN300-107097
SB12453
AMY964
boronic acid, b-(3-aminophenyl)-
m-amino-phenyl-boronic acid
m-aminophenyl boronic-acid
(3-aminophenyl)boronicacid
Z1201617111

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" It is usually treated with eye drops, which has low bioavailability owing to rapid clearance from the ocular surface and leads to poor patient compliance and side effects."( Phenylboronic acid-tethered chondroitin sulfate-based mucoadhesive nanostructured lipid carriers for the treatment of dry eye syndrome.
Li, J; Liu, D; Pan, W; Song, Y; Tan, G; Yu, Y, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" A dose-response curve was obtained between luminescence intensity and HbA(1c) concentration using a fully automated boronate affinity immunoassay."( Detection of HbA(1c) by boronate affinity immunoassay using bacterial magnetic particles.
Matsunaga, T; Tanaka, T, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency44.66840.011212.4002100.0000AID1030
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamaseStaphylococcus aureusKi7.30007.30007.30007.3000AID1799472
Beta-lactamaseEscherichia coli K-12Ki7.30000.02703.64137.3000AID1799472; AID238690; AID38398
Beta-lactamaseEnterobacter cloacaeKi7.30007.30007.50007.7000AID1799472
Angiotensin-converting enzymeRattus norvegicus (Norway rat)Ki7.30000.00011.96427.3000AID38398
Beta-lactamase TEMEscherichia coliKi7.30000.02701.82347.3000AID1799472
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)IC50 (µMol)12.58920.00111.095810.0000AID1483460
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
antibiotic catabolic processBeta-lactamaseEscherichia coli K-12
response to antibioticBeta-lactamaseEscherichia coli K-12
chemotaxisEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
immune responseEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
phospholipid catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
positive regulation of epithelial cell migrationEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
vesicle-mediated transportEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
sphingolipid catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
regulation of cell migrationEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
phosphatidylcholine catabolic processEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
cell motilityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
positive regulation of lamellipodium morphogenesisEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
beta-lactamase activityBeta-lactamaseEscherichia coli K-12
hydrolase activityBeta-lactamaseEscherichia coli K-12
nucleic acid bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
lysophospholipase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
scavenger receptor activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
calcium ion bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
zinc ion bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
hydrolase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
polysaccharide bindingEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
alkylglycerophosphoethanolamine phosphodiesterase activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
phosphodiesterase I activityEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
outer membrane-bounded periplasmic spaceBeta-lactamaseEscherichia coli K-12
periplasmic spaceBeta-lactamaseEscherichia coli K-12
extracellular spaceEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
plasma membraneEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
extracellular spaceEctonucleotide pyrophosphatase/phosphodiesterase family member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID482996Inhibition of AmpC beta lactamase by spectrophotometry2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Structural study of phenyl boronic acid derivatives as AmpC beta-lactamase inhibitors.
AID437828Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X assessed as residual activity at 1000 uM preincubated for 4 hrs before addition of substrate mixture of (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid and 5,5'-dithiobis(2-nitroben2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors.
AID238690Apparent inhibition constant against Escherichia coli AmpC beta-lactamase2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
AID437817Inhibition of Actinomadura sp. R39 penicillin-binding protein assessed as residual activity at 1000 uM preincubated for 60 mins before addition of substrate mixture of (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid and 5,5'-dithiobis(2-nitrobenzoic ac2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors.
AID38398Inhibitory activity against Escherichia coli AmpC beta-lactamase.1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
AID1483460Inhibition of full length human C-terminal 6-His-tagged ATXbeta using FS-3 as substrate preincubated for 20 mins followed by substrate addition by fluorescence assay2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes.
AID437825Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X assessed as residual activity at 1000 uM preincubated for 60 mins before addition of substrate mixture of (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid and 5,5'-dithiobis(2-nitroben2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors.
AID1497003Inhibition of bacterial AmpC2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Boronic acid inhibitors of the class A β-lactamase KPC-2.
AID1799472Inhibition Assay from Article 10.1016/S1074-5521(01)00034-5: \\Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase.\\2001Chemistry & biology, Jun, Volume: 8, Issue:6
Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (161)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (9.32)18.7374
1990's14 (8.70)18.2507
2000's38 (23.60)29.6817
2010's77 (47.83)24.3611
2020's17 (10.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.82 (24.57)
Research Supply Index5.12 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other166 (99.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]